AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.
Epistemonikos ID: f8a23f7b9d9bb3cbc9287a39118ef5b9557af6d0
First added on: Oct 18, 2024